Showing posts with label
Intellia Therapeutics
.
Show all posts
Showing posts with label
Intellia Therapeutics
.
Show all posts
Monday, August 25, 2025
Intellia Therapeutics (NTLA) — Investor Brief (Aug 2025) - A leader in Crispr/Gene editing advancements!
›
As NTLA's phase 3 trials continue to show signs of real breakthroughs, there may eventually be takeover offers. (Speculation) Full dis...
Saturday, January 18, 2025
Intellia Therapeutics newest breakthrough signals a bright future for treating serious hereditary conditions, offering profound implications for millions of patients worldwide.
›
Intellia Therapeutics is one of the leading companies at the forefront of developing in vivo (inside the body) CRISPR/Cas9 gene editing th...
›
Home
View web version
